1.Study on the comparative analysis of the efficacy of transmesenteric vein extrahepatic portosystemic shunt and transjugular intrahepatic portosystemic shunt in the treatment of cavernous transformation of portal vein.
Ya Dong ZHU ; Wei Xiao LI ; Ming Zhe CUI ; Heng WANG ; Hai Peng YANG ; Shui Ting ZHAI
Chinese Journal of Hepatology 2023;31(1):90-95
Objective: To compare the safety and efficacy of transmesenteric vein extrahepatic portosystemic shunt (TEPS) and transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of cavernous transformation of the portal vein (CTPV). Methods: The clinical data of CTPV patients with patency or partial patency of the superior mesenteric vein treated with TIPS or TEPS treatment in the Department of Vascular Surgery of Henan Provincial People's Hospital from January 2019 to December 2021 were selected. The differences in baseline data, surgical success rate, complication rate, incidence rate of hepatic encephalopathy, and other related indicators between TIPS and TEPS group were statistically analyzed by independent sample t-test, Mann-Whitney U test, and Chi-square test. Kaplan-Meier survival curve was used to calculate the cumulative patency rate of the shunt and the recurrence rate of postoperative portal hypertension symptoms in both groups. Results: The surgical success rate (100% vs. 65.52%), surgical complication rate (6.67% vs. 36.84%), cumulative shunt patency rate (100% vs. 70.70%), and cumulative symptom recurrence rate (0% vs. 25.71%) of the TEPS group and TIPS group were statistically significantly different (P < 0.05). The time of establishing the shunt [28 (2141) min vs. 82 (51206) min], the number of stents used [1 (12) vs. 2 (15)], and the length of the shunt [10 (912) cm vs. 16 (1220) cm] were statistically significant between the two groups (t = -3.764, -4.059, -1.765, P < 0.05). The incidence of postoperative hepatic encephalopathy in the TEPS group and TIPS group was 6.67% and 15.79% respectively, with no statistically significant difference (Fisher's exact probability method, P = 0.613). The pressure of superior mesenteric vein decreased from (29.33 ± 1.99) mmHg to (14.60 ± 2.80) mmHg in the TEPS group and from (29.68 ± 2.31) mmHg to (15.79 ± 3.01) mmHg in TIPS group after surgery, and the difference was statistically significant (t = 16.625, 15.959, P < 0.01). Conclusion: The best indication of TEPS is in CTPV patients with patency or partial patency of the superior mesenteric vein. TEPS improves the accuracy and success rate of surgery and reduces the incidence of complications.
Humans
;
Portal Vein/surgery*
;
Portasystemic Shunt, Transjugular Intrahepatic/methods*
;
Hepatic Encephalopathy/etiology*
;
Treatment Outcome
;
Hypertension, Portal/complications*
;
Retrospective Studies
;
Gastrointestinal Hemorrhage/etiology*
2.Chinese expert surgical procedure consensus on open pericardial devascularization(2021).
Chinese Journal of Surgery 2022;60(5):424-431
Although the treatment strategy of esophageal and gastric varices bleeding in portal hypertension has been diversified and multidisciplinary now,the surgical treatment represented by pericardial devascularization operation will still play an important and irreplaceable role in China. In order to standardize the surgical procedure,guide clinical practice and improve the level of surgical treatment of portal hypertension,Chinese Society of Spleen and Portal Hypertension Surgery,Chinese Surgical Society,Chinese Medical Association organized Chinese experts to formulate this consensus. The main contents include:the position of surgical treatment,surgical indications and contraindications,preoperative evaluation,key points and precautions of surgical procedure,perioperative treatment,prevention and treatment of postoperative complications. The consensus emphasizes the standardization of surgical treatment of portal hypertension,pay attention to the prevention and treatment of postoperative portal vein thrombosis,and expect to provide surgeons with clinical guidance.
Consensus
;
Esophageal and Gastric Varices
;
Gastrointestinal Hemorrhage/etiology*
;
Humans
;
Hypertension, Portal/surgery*
;
Liver Cirrhosis/complications*
;
Retrospective Studies
;
Splenectomy/adverse effects*
3.Research Progress in Chinese Medicine Preparations for Promoting Blood Circulation and Removing Blood Stasis for Cirrhotic Patients with Portal Vein Thrombosis Following Splenectomy.
Ding-Qi ZHANG ; Yong-Ping MU ; Ying XU ; Jia-Mei CHEN ; Ping LIU ; Wei LIU
Chinese journal of integrative medicine 2022;28(9):855-863
This article presented an overview of the therapeutic effects of Chinese medicine (CM) preparations for promoting blood circulation and removing blood stasis for patients with portal vein thrombosis (PVT) after splenectomy. Based on published clinical researches of CM preparations for PVT after splenectomy in patients with cirrhotic portal hypertension (CPH), this paper evaluated the incidence of PVT, and explored potential active components and mechanisms of CM preparations. Safflower Yellow Injection, Danshen Injection () Danhong Injection (), and Compound Danshen Dropping Pill () achieved good curative effect alone or combined with anticoagulant therapy. In addition, Compound Biejia Ruangan Tablet () and Anluo Huaxian Pill () can also significantly improve the hemodynamic disorders of portal vein system in patients with cirrhosis. Considering the role of CM preparations in ameliorating the incidence of PVT after splenectomy in patients with CPH, we suggested that future research should provide more attention to CM alone or CM combined with anticoagulant for cirrhosis with PVT.
Anticoagulants/therapeutic use*
;
Humans
;
Hypertension, Portal/drug therapy*
;
Liver Cirrhosis/surgery*
;
Medicine, Chinese Traditional/adverse effects*
;
Portal Vein
;
Risk Factors
;
Splenectomy/adverse effects*
;
Venous Thrombosis/etiology*
4.Construction of Transjugular Intrahepatic Portosystemic Shunt: Bare Metal Stent/Stent-graft Combination versus Single Stent-graft, a Prospective Randomized Controlled Study with Long-term Patency and Clinical Analysis.
Chang-Ming WANG ; Xuan LI ; Jun FU ; Jing-Yuan LUAN ; Tian-Run LI ; Jun ZHAO ; Guo-Xiang DONG
Chinese Medical Journal 2016;129(11):1261-1267
BACKGROUNDBalanced adjustment of the portal vein shunt volume during a transjugular intrahepatic portosystemic shunt (TIPS) is critical for maintaining liver perfusion and decreasing the incidence of liver insufficiency. A stent-graft is proved to be superior to a bare metal stent (BMS) for the construction of a TIPS. However, the clinical results of the combination application of stents and stent-grafts have not been determined. This study aimed to compare the technique of using a combination of stents and stent-grafts with using a single stent-graft to construct a TIPS.
METHODSFrom April 2011 to November 2014, a total of fifty patients were randomly assigned to a stents-combination group (Group I, n = 28) or a stent-graft group (Group II, n = 22). Primary patency rates were calculated. Clinical data, including the technical success rate, bleeding control results, incidence of encephalopathy, liver function preservation, and survival rate, were assessed.
RESULTSTechnically, the success rate was 100% for both groups. The primary patency rates at 1, 2, and 3 years for Group I were 96%, 84%, and 77%, respectively; for Group II, they were 90%, 90%, and 78%, respectively. The survival rates at 1, 2, and 3 years for Group I were 79%, 74%, and 68%, respectively; for Group II, they were 82%, 82%, and 74%, respectively. The incidence of hepatic encephalopathy was 14.3% for Group I and 13.6% for Group II. The Child-Pugh score in Group I was stable at the end of the follow-up but had significantly increased in Group II (t = -2.474, P = 0.022).
CONCLUSIONSThe construction of a TIPS with either the single stent-graft or BMS/stent-graft combination is effective for controlling variceal bleeding. The BMS/stent-graft combination technique is superior to the stent-graft technique in terms of hepatic function preservation indicated by the Child-Pugh score. However, considering the clinical results of the TIPS, the two techniques are comparable in their primary shunt patency, incidence of encephalopathy and patient survival during the long-term follow-up.
Aged ; Female ; Hepatic Encephalopathy ; diagnosis ; etiology ; Humans ; Hypertension, Portal ; complications ; mortality ; surgery ; Male ; Middle Aged ; Polytetrafluoroethylene ; Portal Vein ; surgery ; Portasystemic Shunt, Transjugular Intrahepatic ; adverse effects ; methods ; Postoperative Complications ; Prospective Studies ; Stents ; Treatment Outcome
5.Laparoscopic versus open splenectomy and devascularization for massive splenomegaly due to portal hypertension.
Yao LIU ; Long ZHAO ; Yong TANG ; Yu ZHANG ; Shen-Chao SHI ; Fu-Xiao XIE ; Chi-Dan WAN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(6):876-880
Although the clinical benefit of laparoscopic splenectomy and devascularization (LSD) has been elaborated in many studies, its application in massive splenomegaly remains controversial. We conducted a retrospective research to assess the curative efficacy of LSD for massive splenomegaly due to portal hypertension. Forty-seven patients with massive splenomegaly due to portal hypertension were enrolled in this study, and divided into two groups. Twenty-one patients underwent open splenectomy and devascularization (OSD) from June 2010 to October 2012 (OSD group). From March 2013 to February 2015, LSD was performed on 26 patients (LSD group). Perioperative variables were analyzed. Compared to OSD, LSD was associated with less blood loss (241.9±110.0 mL vs. 319.0±139.5 mL, P<0.05), more rapid resumption of oral diet (2.46±0.95 days vs. 3.76±1.09 days, P<0.05), and shorter postoperative hospital stay (5.35±1.65 days vs. 7.24±1.55 days, P<0.05). It was concluded that for patients with massive splenomegaly due to portal hypertension, LSD is feasible and as safe as OSD.
Adult
;
Blood Loss, Surgical
;
Female
;
Humans
;
Hypertension, Portal
;
complications
;
Laparoscopy
;
adverse effects
;
methods
;
Length of Stay
;
statistics & numerical data
;
Male
;
Middle Aged
;
Splenectomy
;
adverse effects
;
methods
;
Splenomegaly
;
etiology
;
surgery
;
Vascular Surgical Procedures
;
adverse effects
;
methods
6.Health-Related Quality of Life in Children with Biliary Atresia Living with Native Livers.
Annals of the Academy of Medicine, Singapore 2016;45(2):61-68
INTRODUCTIONThis study aimed to quantify and investigate factors affecting the health-related quality of life (HRQoL) in children with biliary atresia (BA) living with their native livers.
MATERIALS AND METHODSA cross-sectional study on the HRQoL using the PedsQL4.0 generic core scales in children with BA aged between 2 to 18 years followed up at the University Malaya Medical Centre (UMMC) in Malaysia was conducted. Two groups, consisting of healthy children and children with chronic liver disease (CLD) caused by other aetiologies, were recruited as controls.
RESULTSChildren with BA living with their native livers (n = 36; median (range) age: 7.4 (2 to 18) years; overall HRQoL score: 85.6) have a comparable HRQoL score with healthy children (n = 81; median age: 7.0 years; overall HQRoL score: 87.4; P = 0.504) as well as children with CLD (n = 44; median age: 4.3 years; overall score: 87.1; P = 0.563). The HRQoL of children with BA was not adversely affected by having 1 or more hospitalisations in the preceding 12 months, the presence of portal hypertension, older age at corrective surgery (>60 days), a lower level of serum albumin (≤34 g/L) or a higher blood international normalised ratio (INR) (≥1.2). Children who had liver transplantation for BA did not have a significantly better HRQoL as compared to those who had survived with their native livers (85.4 vs 85.7, P = 0.960).
CONCLUSIONHRQoL in children with BA living with their native livers is comparable to healthy children.
Adolescent ; Age Factors ; Biliary Atresia ; complications ; physiopathology ; psychology ; surgery ; Case-Control Studies ; Child ; Child, Preschool ; Chronic Disease ; Cross-Sectional Studies ; Female ; Health Status ; Humans ; Hypertension, Portal ; etiology ; physiopathology ; psychology ; Liver Diseases ; physiopathology ; psychology ; Liver Transplantation ; Malaysia ; Male ; Quality of Life ; Serum Albumin
7.Clinical outcomes of transjugular intrahepatic portosystemic shunt for portal hypertension: Korean multicenter real-practice data.
Hyung Ki KIM ; Yoon Jun KIM ; Woo Jin CHUNG ; Soon Sun KIM ; Jae Jun SHIM ; Moon Seok CHOI ; Do Young KIM ; Dae Won JUN ; Soon Ho UM ; Sung Jae PARK ; Hyun Young WOO ; Young Kul JUNG ; Soon Koo BAIK ; Moon Young KIM ; Soo Young PARK ; Jae Myeong LEE ; Young Seok KIM
Clinical and Molecular Hepatology 2014;20(1):18-27
BACKGROUND/AIMS: This retrospective study assessed the clinical outcome of a transjugular intrahepatic portosystemic shunt (TIPS) procedure for managing portal hypertension in Koreans with liver cirrhosis. METHODS: Between January 2003 and July 2013, 230 patients received a TIPS in 13 university-based hospitals. RESULTS: Of the 229 (99.6%) patients who successfully underwent TIPS placement, 142 received a TIPS for variceal bleeding, 84 for refractory ascites, and 3 for other indications. The follow-up period was 24.9+/-30.2 months (mean+/-SD), 74.7% of the stents were covered, and the primary patency rate at the 1-year follow-up was 78.7%. Hemorrhage occurred in 30 (21.1%) patients during follow-up; of these, 28 (93.3%) cases of rebleeding were associated with stent dysfunction. Fifty-four (23.6%) patients developed new hepatic encephalopathy, and most of these patients were successfully managed conservatively. The cumulative survival rates at 1, 6, 12, and 24 months were 87.5%, 75.0%, 66.8%, and 57.5%, respectively. A high Model for End-Stage Liver Disease (MELD) score was significantly associated with the risk of death within the first month after receiving a TIPS (P=0.018). Old age (P<0.001), indication for a TIPS (ascites vs. bleeding, P=0.005), low serum albumin (P<0.001), and high MELD score (P=0.006) were associated with overall mortality. CONCLUSIONS: A high MELD score was found to be significantly associated with early and overall mortality rate in TIPS patients. Determining the appropriate indication is warranted to improve survival in these patients.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Asian Continental Ancestry Group
;
End Stage Liver Disease/pathology
;
Female
;
Follow-Up Studies
;
Hemorrhage/etiology
;
Hepatic Encephalopathy/etiology
;
Hospitals, University
;
Humans
;
Hypertension, Portal/*diagnosis/mortality/surgery
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Odds Ratio
;
*Portasystemic Shunt, Transjugular Intrahepatic
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Severity of Illness Index
;
Survival Rate
;
Treatment Outcome
;
Young Adult
8.Preoperative risk factors of portal venous thrombosis after splenectomy and gastric pericardial devascularization for portal hypertension.
Jianbo HAN ; Yongxiang YI ; Hai DING ; Junmao LIU ; Yufeng ZHANG ; Liang HU ; Liang ZHAO ; Tao LIU
Chinese Journal of Hepatology 2014;22(10):739-743
OBJECTIVETo investigate the preoperative risk factors of portal venous thrombosis (PVT) after splenectomy and gastric pericardial devascularization in patients with liver cirrhosis and portal hypertension.
METHODSClinical data was collected for 127 patients who underwent splenectomy and gastric pericardial devascularization for portal hypertension at our hospital between January 2010 and December 2012.The patient data were analyzed retrospectively according to patient status of presence or absence of PVT postoperatively.The preoperative risk factors of PVT were statistically analyzed.
RESULTSThere were no significant differences between the postoperative PVT-positive and-negative groups in regards to sex, age, receipt of emergency surgery, presence of ascites, admission to hospital for upper gastrointestinal bleeding, grade of esophageal-gastric varices, Child-Pugh classification, spleen vein diameter, liver function (as determined by levels of alanine aminotransferase, total bilirubin, direct bilirubin, albumin, globulin, cholinesterase, and gamma-glutamyltransferase), renal function (as determined by creatinine level), and coagulation function (as determined by prothrombin time, prothrombin activity degree, activated partial thromboplastin time, international normalized ratio, fibrinogen, thrombin time, and antithrombin III).However, there were significant differences between the groups for the parameters of postoperative PVT presence, upper gastric bleeding history, aspartate aminotransferase level, and blood urea nitrogen level (all P less than 0.05).Portal vein diameter and history of upper gastric bleeding were both identified as independent risk factors for PVT (P less than 0.05).Incidence of postoperative PVT was higher in patients who had portal vein diameter > 13.15 mm (cutoff value of 13.75 mm) and in patients who had a history of upper gastric bleeding.
CONCLUSIONPortal vein diameter and history of upper gastric bleeding were independent risk factors for PVT occurrence after splenectomy and gastric pericardial devascularization in patients with liver cirrhosis and portal hypertension.
Antithrombin III ; Esophageal and Gastric Varices ; Gastrointestinal Hemorrhage ; Humans ; Hypertension, Portal ; surgery ; Incidence ; Liver Cirrhosis ; Portal Vein ; Retrospective Studies ; Risk Factors ; Splenectomy ; Stomach ; blood supply ; surgery ; Venous Thrombosis ; epidemiology ; etiology ; gamma-Glutamyltransferase
9.A prospective randomized trial of selective versus nonselective esophagogastric devascularization for portal hypertension.
Chao WANG ; Liang XIAO ; Juan HAN ; Chang-e JIN ; Yin PENG ; Zhen YANG
Journal of Huazhong University of Science and Technology (Medical Sciences) 2014;34(4):563-568
Cirrhosis with portal hypertension is a common disease which has a significant impact on the quality of patients' life. Esophagogastric devascularization (EGDV) has been demonstrated to be an effective method to treat portal hypertension, however certain complications are associated with it. The purpose of this study was to evaluate the effectiveness and clinical outcome of the selective EGDV (sEGDV) for the treatment of portal hypertension. The study was conducted prospectively from Jan. 1 2011 to Dec. 31, 2012, and 180 patients were randomized to the sEGDV group (n=90) or the non-sEGDV (n-sEGDV) group (n=90). Patients' demographics, preoperative lab test results and operative details were comparable between the two groups. Postoperative and short-term complications were analyzed in two groups. There was statistically significant difference (P<0.01) in the PVF reduction between the two groups. Post-operative complications showed no statistically significant difference between the two groups in the incidence of bleeding, ascites, acute portal vein thrombosis, fever and hepatic encephalopathy. Mortality between two groups was comparable. The incidence of splenic fossa effusion after the surgery was lower in sEGDV group than in n-sEGDV group. There were no significant differences in the short-term follow-up data such as esophageal varices and portal hypertensive gastropathy (P>0.05). It is suggested that sEGDV is a safe, simple and effective surgical procedure. It has both the advantages of the shunt and devascularization because it preserves body's voluntary diversion. With the advantage of low incidence of postoperative complications, it is an ideal surgical approach for the treatment of portal hypertension.
Adult
;
Esophagus
;
blood supply
;
surgery
;
Female
;
Gastrointestinal Hemorrhage
;
etiology
;
pathology
;
physiopathology
;
Hepatic Encephalopathy
;
pathology
;
physiopathology
;
Humans
;
Hypertension, Portal
;
pathology
;
physiopathology
;
surgery
;
In Vitro Techniques
;
Male
;
Middle Aged
;
Postoperative Complications
;
pathology
;
physiopathology
;
Prospective Studies
;
Stomach
;
blood supply
;
surgery
;
Thrombosis
;
etiology
;
pathology
;
physiopathology
10.A Case of Liver Fibrosis with Splenomegaly after Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer.
Gu Hyum KANG ; Hee Seok MOON ; Eaum Seok LEE ; Seok Hyun KIM ; Jae Kyu SUNG ; Byung Seok LEE ; Hyun Yong JEONG ; Heon Young LEE ; Dae Young KANG
Journal of Korean Medical Science 2013;28(12):1835-1838
Previous studies reported that oxaliplatin is associated with sinusoidal obstruction syndrome. However few reports on oxaliplatin induced liver fibrosis are found in the literature. Furthermore pathogenesis of liver fibrosis is not well known. We report a case of 45-yr-old Korean man in whom liver fibrosis with splenomegaly developed after 12 cycles of oxaliplatin based adjuvant chemotherapy for colon cancer (T4N2M0). Thorough history taking and serological examination revealed no evidence of chronic liver disease. Restaging CT scans demonstrated a good response to chemotherapy. Five month after chemotherapy, he underwent right hepatectomy due to isolated metastatic lesion. The liver parenchyma showed diffuse sinusoidal dilatation and centrilobular vein fibrosis with necrosis without steatosis. We could conclude that splenomegaly was due to perisinusoidal liver fibrosis and liver cell necrosis induced portal hypertension by oxaliplatin. In addition, to investigate the pathogenesis of liver fibrosis, immunohistochemical stains such as CD31 and alpha-smooth muscle actin (alpha-SMA) were conducted with control group. The immunohistochemical stains for CD31 and alpha-SMA were positive along the sinusoidal space in the patient, while negative in the control group. Chemotherapy with oxaliplatin induces liver fibrosis which should be kept in mind as a serious complication.
Actins/metabolism
;
Antigens, CD31/metabolism
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Camptothecin/*analogs & derivatives/therapeutic use
;
Chemotherapy, Adjuvant
;
Colonic Neoplasms/*drug therapy
;
Fluorouracil/therapeutic use
;
Humans
;
Hypertension, Portal/etiology
;
Immunohistochemistry
;
Leucovorin/therapeutic use
;
Liver Cirrhosis/*diagnosis/etiology/pathology
;
Liver Neoplasms/secondary/surgery
;
Male
;
Middle Aged
;
Organoplatinum Compounds/*administration & dosage/adverse effects/therapeutic use
;
Splenomegaly/*diagnosis/etiology
;
Thrombocytopenia/etiology
;
Tomography, X-Ray Computed

Result Analysis
Print
Save
E-mail